Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Doris Makari, Rachel M Layman, Hope S Rugo · 2024
Read Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness by Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Doris Makari, Rachel M Layman, Hope S Rugo (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11630750.txt.
Description
Cancer trials often bar patients with heart disease, leaving doctors guessing how treatments perform in that large group. Adam Brufsky and co-authors filled the gap with clinic records in this 2024 study. The patients had hormone-driven metastatic breast cancer plus cardiovascular disease. First treatment paired a targeted pill, palbociclib, with a hormone blocker, or used the blocker alone.
Records came from a national health database covering 2015 to 2020. Survival and time without cancer growth were compared between the two starts. Treatment patterns, such as dose changes, were also charted. Real-world evidence like this guides care for patients trials leave out. Heart disease should not automatically close the door on effective therapy.
Catalog record
| CREATOR | Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Doris Makari, Rachel M Layman, Hope S Rugo |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |